Fåhraeus Startup & Growth (FSG), a Lund-based venture capital firm, has successfully closed its second fund at €74 million, significantly larger than its previous fund of €26 million. The firm specializes in investing in early-stage technology and life science companies, particularly those at the intersection of these fields. The European Investment Fund (EIF) has invested €20 million, reinforcing FSG's position in the venture capital landscape. With approximately €60 million still available for deployment, FSG intends to target Nordic and European companies, focusing on pharmaceuticals, medtech, and high-margin tech businesses.
Fåhraeus Startup & Growth has successfully closed a new fund at €74 million, focusing on early-stage companies at the intersection of technology and healthcare.
The firm's second fund is notably larger than its first, allowing for more substantial investment in promising Nordic and European tech and life sciences companies.
The European Investment Fund’s €20 million investment highlights FSG's credibility among institutional investors and supports a strategy of long-term backing.
FSG aims to prioritize investments in pharmaceuticals, medtech, and tech sectors, with a strategic approach to identifying opportunities with lower competition.
Collection
[
|
...
]